Forward thinking. Enabling breakthroughs.

Life science innovations drive the future of human health; Precision helps those breakthroughs break though. Transforming data to unlock its true potential. Remaining focused on future needs and developments even as we master the present. At every inflection point we strive to pull the development curve years forward and shift market trajectories ahead, always moving science closer to health.

TRANSFORMING

DATA FOR HEALTH

Today, healthcare is awash in data—creating both a boon and a conundrum. Everyone knows that data contain crucial insights; not everyone knows how to make that data actionable. At Precision, it’s what we do.

Processing terabytes of data in milliseconds, our systems aggregate data from dozens of disparate sources, using turnkey connectors as accelerators to enable interoperability. Domain experts, seasoned biostatisticians, and statistical programmers work together to supply contextual structure. The data are mastered. The meaning behind the numbers becomes clear. And our customers can make real-time decisions with confidence.

That’s transformative.

Data for Precision Medicine
Data for Clinical Trials
Data for Commercialization
Data for Precision Medicine
Data for Clinical Trials
Data for Commercialization

ADVANCE

the gene & cell therapy collective

Innovative modalities—from immunotherapy to gene and cell therapies—hold tremendous promise for patients in need. They also cause tremendous complexity for life sciences companies. Precision is designed specifically to address that complexity.

Consider gene and cell therapy. Our interdisciplinary teams have been tackling clinical, regulatory, and commercial strategies for gene and cell therapies since 2013—and we have worked on nearly all of today’s approved gene and cell therapy products. Concurrently, we’ve been helping shape this evolving therapeutic area: addressing pricing with health technology assessments (HTAs), serving on regulatory committees to determine approval pathways, developing innovative biomarker companion diagnostic strategies, and executing clinical trials from first in human through regulatory submission. Such leadership is central to our ability to accelerate patient access to important new therapies.

Gene and cell therapy clinical development